Evidence map›Paper›PMID 38646933›Full record

ArticleJCI insight2024

Phototoxicity avoidance is a potential therapeutic approach for retinal dystrophy caused by EYS dysfunction.

Yuki Otsuka, Keiko Imamura, Akio Oishi, Kazuhide Asakawa, Takayuki Kondo, Risako Nakai, Mika Suga, Ikuyo Inoue, Yukako Sagara, Kayoko Tsukita and 11 more

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Human-based complexFrontiers in cell and developmental biology · 2025
    Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 1 country.

Yuki OtsukaiPSC-based Drug discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan.
Keiko ImamuraiPSC-based Drug discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan.
Akio OishiDepartment of Ophthalmology and Visual Sciences, Nagasaki University, Nagasaki, Japan.
Kazuhide AsakawaDivision of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Japan.
Takayuki KondoiPSC-based Drug discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan.
Risako NakaiiPSC-based Drug discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan.
Mika SugaiPSC-based Drug discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan.
Ikuyo InoueCenter for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.
Yukako SagaraiPSC-based Drug discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan.
Kayoko TsukitaiPSC-based Drug discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan.
Kaori TeranakaGraduate School of Medicine, Kyoto University, Kyoto, Japan.
Yu NishimuraGraduate School of Medicine, Kyoto University, Kyoto, Japan.
Akira WatanabeGraduate School of Medicine, Kyoto University, Kyoto, Japan.
Kazuhiro UmeyamaMeiji University International Institute for Bio-Resource Research, Kawasaki, Japan.
Nanako OkushimaDivision of Systems Medicine and Gene Therapy, Faculty of Medicine, Saitama Medical University, Saitama, Japan.
Kohnosuke MitaniDivision of Systems Medicine and Gene Therapy, Faculty of Medicine, Saitama Medical University, Saitama, Japan.
Hiroshi NagashimaMeiji University International Institute for Bio-Resource Research, Kawasaki, Japan.
Koichi KawakamiDivision of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Japan.
Keiko MugurumaDepartment of iPS Cell Applied Medicine, Graduate School of Medicine, Kansai Medical University, Hirakata, Osaka, Japan.
Akitaka TsujikawaDepartment of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Haruhisa InoueiPSC-based Drug discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan.
Kyoto University · JPMeiji University · JPNational Institute of Genetics · JPSaitama Medical University · JPKansai Medical University · JPNagasaki University · JPRIKEN BioResource Research Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inherited retinal dystrophies (IRDs) are progressive diseases leading to vision loss. Mutation in the eyes shut homolog (EYS) gene is one of the most frequent causes of IRD. However, the mechanism of photoreceptor cell degeneration by mutant EYS has not been fully elucidated. Here, we generated retinal organoids from induced pluripotent stem cells (iPSCs) derived from patients with EYS-associated retinal dystrophy (EYS-RD). In photoreceptor cells of RD organoids, both EYS and G protein-coupled receptor kinase 7 (GRK7), one of the proteins handling phototoxicity, were not in the outer segment, where they are physiologically present. Furthermore, photoreceptor cells in RD organoids were vulnerable to light stimuli, and especially to blue light. Mislocalization of GRK7, which was also observed in eys-knockout zebrafish, was reversed by delivering control EYS into photoreceptor cells of RD organoids. These findings suggest that avoiding phototoxicity would be a potential therapeutic approach for EYS-RD.

Indexed as

Induced Pluripotent Stem CellsOrganoidsRetinal DystrophiesZebrafishAnimalsEye ProteinsHumansLightMutationRetinaZebrafish ProteinsEye ProteinsEYS protein, humanEYS protein, zebrafishZebrafish ProteinsOphthalmologyRetinopathyStem cells

Identifiers

PMID38646933
PMCPMC11141876
OpenAlexW4395037226

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.